Drug therapy of experimental tuberculosis (TB): improved outcome by combining SQ109, a new diamine antibiotic, with existing TB drugs

Antimicrob Agents Chemother. 2007 Apr;51(4):1563-5. doi: 10.1128/AAC.01326-06. Epub 2007 Jan 22.

Abstract

Substitution of the new diamine antibiotic SQ109 for ethambutol in a mouse model of chronic tuberculosis (TB) improved efficacy of combination drug therapy with first-line TB drugs rifampin and isoniazid, with or without pyrazinamide: at 8 weeks, lung bacteria were 1.5 log10 lower in SQ109-containing regimens.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Adamantane / analogs & derivatives*
  • Adamantane / pharmacology
  • Adamantane / therapeutic use
  • Animal Experimentation
  • Animals
  • Anti-Bacterial Agents / pharmacology
  • Antitubercular Agents / pharmacology*
  • Antitubercular Agents / therapeutic use*
  • Drug Therapy, Combination*
  • Ethylenediamines / pharmacology
  • Ethylenediamines / therapeutic use*
  • Lung
  • Mice
  • Mycobacterium tuberculosis / drug effects*
  • Treatment Outcome
  • Tuberculosis / drug therapy*

Substances

  • Anti-Bacterial Agents
  • Antitubercular Agents
  • Ethylenediamines
  • N-geranyl-N'-(2-adamantyl)ethane-1,2-diamine
  • Adamantane